A. Burgess

In vivo biologic effects of PIXY321, a synthetic hybrid protein of recombinant human granulocyte-macrophage colony-stimulating factor and interleukin-3 in cancer patients with normal hematopoiesis: a phase I study.

D. Williams, M. Andreeff, R. Benjamin, 1995, Blood.

Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thrombocytopenia.

L. Broemeling, R. Benjamin, H. Broxmeyer, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Importance o f P redosing o f R ecombinant H uman Thrombopoietin t o R educe C hemotherapy-Ind uced Early T hrombocytopenia

L. Broemeling, R. Benjamin, H. Broxmeyer, 2003 .

Prognostic factors for survival of patients treated systemically for disseminated melanoma.

Q. Dong, C. Balch, A. Buzaid, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I clinical study of N-(phosphonacetyl)-L-aspartic acid (PALA).

W. Plunkett, E. Freireich, G. Bodey, 1980, Cancer treatment reports.

Initial clinical studies of vindesine.

E. Freireich, M. Valdivieso, G. Bodey, 1981, Cancer treatment reports.

Phase II study of AMSA alone and in combination with DTIC in patients with metastatic melanoma

R. Benjamin, S. Legha, G. Bodey, 1988, Investigational New Drugs.

Effect of cyclophosphamide on the mitomycin-induced syndrome of thrombotic thrombocytopenic purpura.

V. Hug, G. Blumenschein, A. Burgess, 1985, Cancer treatment reports.